A collection of publications and data presentations relevant to Reata's development programs
A review of Alport syndrome epidemiology and the role of inflammation and Nrf2 in chronic kidney disease in patients with Alport syndrome.
This preclinical study evaluated the effects of omaveloxolone and TX63682, a closely related structural analog, in the STAM mouse model of nonalcoholic steatohepatitis (NASH), a progressive form of liver disease.
TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.
The effects of dihydro‐CDDO‐trifluoroethyl amide (dh404), a rodent‐tolerable bardoxolone methyl analog, on the tubulointerstitium, were tested in an Institute of Cancer Research‐derived glomerulonephritis (ICGN) mouse model of kidney disease. The effect of dh404 on mitochondrial function, was assessed using human proximal tubular cells in vitro.
Post-hoc analyses to characterize the relationship between the urine albumin-to-creatinine ratio and estimated glomerular filtration rate in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Post-hoc analyses to characterize changes in body weight in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Post-hoc analyses to characterize changes in kidney function in response to bardoxolone methyl treatment in BEACON, a Phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial of bardoxolone methyl in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
A preclinical investigation on the role of megalin, a protein involved in the tubular reabsorption of albumin and lipid-bound proteins, in changes in albuminuria in animals treated with bardoxolone methyl.